Book References-HyperBook3rdEdition

These are the references for the book “Natural Treatment Solutions for Hyperthyroidism and Graves’ Disease” 3rd Edition:


1, 2

3 Plourde, Elizabeth.  Your Guide to Hysterectomy, Ovary Removal, & Hormone Replacement.  2002: 38-39

4 Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M.; Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States; Thyroid. 1991;1(2):129-35.

Chapter 1: No references

Chapter 2: No references

Chapter 3: No references

Chapter 4:

5  M C Arrieta, L Bistritz, and J B Meddings; Alterations in intestinal permeability; Gut 2008 October; 55(10): 1512-1520

6  Bassi V, Marino G, Iengo A, Fattoruso O, Santinelli C; Autoimmune thyroid diseases and Helicobacter pylori: the correlation is present only in Graves’s disease; World J Gastroenterol. 2012 Mar 14;18(10):1093-7. doi: 10.3748/wjg.v18.i10.1093.

7   Shi W, Liu W, Zhou X, Ye F, Zhang G.; Associations of Helicobacter pylori infection and cytotoxin-associated gene A status with autoimmune thyroid diseases: a meta-analysis; Thyroid. 2013 Apr 2.

8 Nakazawa, Donna Jackson.  The Autoimmune Epidemic.  2006: 106

9 Rafał Płoski,*,1 Konrad Szymański,1 and Tomasz Bednarczuk*; The Genetic Basis of Graves’ Disease; Curr Genomics. 2011 December; 12(8): 542–563

Chapter 5: No references

Chapter 6: No references

Chapter 7:

10 Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, Manji N, Allahabadia A, Armitage M, Chatterjee KV, Lazarus JH, Pearce SH, Vaidya B, Gough SC, Franklyn JA.; Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease; Am J Med. 2010 Feb;123(2):183.e1-9. doi: 10.1016/j.amjmed.2009.06.030.

11 Hemminki K, Li X, Sundquist J, Sundquist K.; The epidemiology of Graves’ disease: evidence of a genetic and an environmental contribution; J Autoimmun. 2010 May;34(3):J307-13. doi: 10.1016/j.jaut.2009.11.019. Epub 2009 Dec 28

12 Lewis MR, Tracy RP.; The role of the immune system in the insulin resistance syndrome; Curr Diab Rep. 2002 Feb;2(1):96-9.

13 Olefsky JM, Glass CK.; Macrophages, inflammation, and insulin resistance; Annu Rev Physiol. 2010;72:219-46. doi: 10.1146/annurev-physiol-021909-135846

14  Lashley FR.; A review of sleep in selected immune and autoimmune disorders; Holist Nurs Pract. 2003 Mar-Apr;17(2):65-80

15  Xu Z, Jin Y.; Main indoor air pollutants and their health impacts; Wei Sheng Yan Jiu. 2003 May;32(3):279-83

16  Gold DR.; Indoor air pollution; Clin Chest Med. 1992 Jun;13(2):215-29

17  Prummel MF, Wiersinga WM.; Smoking and risk of Graves’ disease; JAMA. 1993 Jan 27;269(4):479-82

18  Johnson EO, Calogero AE, Konstandi M, Kamilaris TC, Vignera SL, Chrousos GP.; Effects of experimentally induced hyperthyroidism on central hypothalamic-pituitary-adrenal axis function in rats: in vitro and in situ studies; Pituitary. 2013 Jun;16(2):275-86. doi: 10.1007/s11102-012-0417-5.

Chapter 8:

19 (Change to 18) Nakazawa, Donna Jackson.  The Autoimmune Epidemic.  2006: 250

20  (Change to 19) Wilson, Dr. James L. Wilson.  Adrenal Fatigue, The 21st Century Stress Syndrome.  2010: 270

21 (Change to 20) The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves’ disease. By: Fukao, Atsushi; Takamatsu, Junta; Murakami, Yasuhiro;Sakane, Sadaki; Miyauchi, Akira; Kuma, Kanji; Hayashi, Shunichiro; Hanafusa, Toshiaki. Clinical Endocrinology, May2003, Vol. 58 Issue 5, p550-555, 6p

22 (Change to 21) Santos AM, Nobre EL, Garcia e Costa J, Nogueira PJ, Macedo A, De Castro JJ, Teles AG.; Grave’s disease and stress; Acta Med Port. 2002 Nov-Dec;15(6):423-7.

23 (Change to 22) Radosavljević VR, Janković SM, Marinković JM.; Stressful life events in the pathogenesis of Graves’ disease; Eur J Endocrinol. 1996 Jun;134(6):699-701.

24 (Change to 23) Inder WJ, Dimeski G, Russell A.; Measurement of salivary cortisol in 2012 – laboratory techniques and clinical indications; Clin Endocrinol (Oxf). 2012 Nov;77(5):645-51. doi: 10.1111/j.1365-2265.2012.04508

25 (Change to 24) Aardal-Eriksson E, Karlberg BE, Holm AC.; Salivary cortisol–an alternative to serum cortisol determinations in dynamic function tests; Clin Chem Lab Med. 1998 Apr;36(4):215-22

26 (Change to 25) Duplessis C, Rascona D, Cullum M, Yeung E.; Salivary and free serum cortisol evaluation; Mil Med. 2010 May;175(5):340-6;

27 (Change to 26) Vining RF, McGinley RA, Maksvytis JJ, Ho KY.; Salivary cortisol: a better measure of adrenal cortical function than serum cortisol; Ann Clin Biochem. 1983 Nov;20 (Pt 6):329-35 (27) (28) (29) (30)

Chapter 9:

31   **Might change reference

Chapter 10: (32) (33)

Chapter 11:

34 Kapadia KB, Bhatt PA, Shah JS.; Association between altered thyroid state and insulin resistance; J Pharmacol Pharmacother. 2012 Apr;3(2):156-60. doi: 10.4103/0976-500X.95517.

35 Gabriela Brenta; Why Can Insulin Resistance Be a Natural Consequence of Thyroid Dysfunction?; J. Thyroid Res 2011; 152850

36 Maratou E, Hadjidakis DJ, Peppa M, Alevizaki M, Tsegka K, Lambadiari V, Mitrou P, Boutati E, Kollias A, Economopoulos T, Raptis SA, Dimitriadis G.; Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism; Eur J Endocrinol. 2010 Oct;163(4):625-30. doi: 10.1530/EJE-10-0246. Epub 2010 Jul 19

37 Williams G.; Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-α and GPER signalling; Mol Cell Endocrinol. 2012 Apr 4;351(2):269-78. doi: 10.1016/j.mce.2011.12.017. Epub 2012 Jan 5

38 Bhattacharyya S, O-Sullivan I, Katyal S, Unterman T, Tobacman JK.; Exposure to the common food additive carrageenan leads to glucose intolerance, insulin resistance and inhibition of insulin signalling in HepG2 cells and C57BL/6J mice; Diabetologia. 2012 Jan;55(1):194-203. doi: 10.1007/s00125-011-2333-z. Epub 2011 Oct 20

39 Tobacman JK.; Review of harmful gastrointestinal effects of carrageenan in animal experiments; Environ Health Perspect. 2001 Oct;109(10):983-94

Chapter 12: (40) (41) (42) (43) (44) (45)

46 Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis. By: Nacamulli, Davide; Mian, Caterina; Petricca, Daniela; Lazzarotto, Francesca; Barollo, Susi; Pozza, Dina; Masiero, Stefano; Faggian, Diego; Plebani, Mario; Girelli, Maria E.; Mantero, Franco; Betterle, Corrado. Clinical Endocrinology, Oct2010, Vol. 73 Issue 4, p535-539, 5p, 1 Black and White Photograph, 1 Chart, 3 Graphs

47 Leonidas H. Duntas; The Evolving Role of Selenium in the Treatment of Graves’ Disease and Ophthalmopathy; Journal of Thyroid Research Volume 2012 (2012), Article ID 736161, 6 pages doi:10.1155/2012/736161

48 Vrca VB, Skreb F, Cepelak I, Romic Z, Mayer L.; Supplementation with antioxidants in the treatment of Graves’ disease; the effect on glutathione peroxidase activity and concentration of selenium; Clin Chim Acta. 2004 Mar;341(1-2):55-63

49 Gerster H; Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)?; Int J Vitam Nutr Res. 1998;68(3):159-73

50 Vigerust NF, Bjørndal B, Bohov P, Brattelid T, Svardal A, Berge RK.; Krill oil versus fish oil in modulation of inflammation and lipid metabolism in mice transgenic for TNF-α; Eur J Nutr. 2013 Jun;52(4):1315-25. doi: 10.1007/s00394-012-0441-2. Epub 2012 Aug 25

51 Vieth R.; Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety; Am J Clin Nutr. 1999 May;69(5):842-56

52 Garland CF, French CB, Baggerly LL, Heaney RP.; Vitamin D supplement doses and serum 25-hydroxyvitamin D in the range associated with cancer prevention; Anticancer Res. 2011 Feb;31(2):607-11 (53) (54)

55 Resch U, Helsel G, Tatzber F, Sinzinger H.; Antioxidant status in thyroid dysfunction; Clin Chem Lab Med. 2002 Nov;40(11):1132-4

56 Antonio Mancini, Roberto Festa, Sebastiano Raimondo, Alfredo Pontecorvi, and Gian Paolo Littarru; Hormonal Influence on Coenzyme Q10 Levels in Blood Plasma; Int J Mol Sci. 2011; 12(12): 9216–9225.

57 Pandolfi C, Ferrari D, Stanic I, Pellegrini L.; Circulating levels of CoQ10 in hypo- and hyperthyroidism; Minerva Endocrinol. 1994 Sep;19(3):139-42

58 Asayama K, Kato K.; Oxidative muscular injury and its relevance to hyperthyroidism; Free Radic Biol Med. 1990;8(3):293-303

59 Ogura F, Morii H, Ohno M, Ueno T, Kitabatake S, Hamada N, Ito K.; Serum coenzyme Q10 levels in thyroid disorders; Horm Metab Res. 1980 Oct;12(10):537-40

60 Kishi T, Watanabe T, Folkers K.; Bioenergetics in clinical medicine XV. Inhibition of coenzyme Q10-enzymes by clinically used adrenergic blockers of beta-receptors; Res Commun Chem Pathol Pharmacol. 1977 May;17(1):157-64

61 Sarter B.; Coenzyme Q10 and cardiovascular disease: a review; J Cardiovasc Nurs. 2002 Jul;16(4):9-20

62 Marcoff L, Thompson PD.; The role of coenzyme Q10 in statin-associated myopathy: a systematic review; J Am Coll Cardiol. 2007 Jun 12;49(23):2231-7

63 Bargossi AM, Grossi G, Fiorella PL, Gaddi A, Di Giulio R, Battino M.; Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors; Mol Aspects Med. 1994;15 Suppl:s187-93 (64) (65) (66) (67) (68)

69 Wu G, Fang YZ, Yang S, Lupton JR, Turner ND.; Glutathione metabolism and its implications for health; J Nutr. 2004 Mar;134(3):489-92 (70) (71) (72)

73 Ramadan G, Al-Kahtani MA, El-Sayed WM; Anti-inflammatory and anti-oxidant properties of Curcuma longa (turmeric) versus Zingiber officinale (ginger) rhizomes in rat adjuvant-induced arthritis; Inflammation. 2011 Aug;34(4):291-301. doi: 10.1007/s10753-010-9278-0

74 Jurenka JS.; Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research; Altern Med Rev. 2009 Jun;14(2):141-53

75 Bengmark S.; Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases; JPEN J Parenter Enteral Nutr. 2006 Jan-Feb;30(1):45-51

76 Ghanim H, Sia CL, Korzeniewski K, Lohano T, Abuaysheh S, Marumganti A, Chaudhuri A, Dandona P; A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal; J Clin Endocrinol Metab. 2011 May;96(5):1409-14. doi: 10.1210/jc.2010-1812. Epub 2011 Feb 2

77 Das S, Das DK.; Anti-inflammatory responses of resveratrol; Inflamm Allergy Drug Targets. 2007 Sep;6(3):168-73

78 Rieder SA, Nagarkatti P, Nagarkatti M.; Multiple anti-inflammatory pathways triggered by resveratrol lead to amelioration of staphylococcal enterotoxin B-induced lung injury; Br J Pharmacol. 2012 Nov;167(6):1244-58

79 Wang Y, Leung LK.; Pharmacological concentration of resveratrol suppresses aromatase in JEG-3 cells; Toxicol Lett. 2007 Sep 28;173(3):175-80. Epub 2007 Aug 2 (80)

Chapter 13: (81) (82) (83) (85) (85) (86) (87) (88) (89) (90) (91) (92)

93 Brownstein, Dr. David .  Iodine, Why You Need It, Why You Can’t Live Without It.  2009: 48 (94) (95) (96)

97 Clinical Endocrinology; Sep2009, Vol. 71 Issue 3, p440-445, 6p, 3 Charts, 1 Graph

98 The Effect of Small Doses of Stable Iodine in Patients with Hyperthyroidism.. By: Volpe, Robert; Johnston, MacAllister W.. Annals of Internal Medicine, Apr62, Vol. 56 Issue 4, p577, 13p

99 Delange F, Lecomte P.; Iodine supplementation: benefits outweigh risks; Drug Saf. 2000 Feb;22(2):89-95

100 Brownstein, Dr. David .  Iodine, Why You Need It, Why You Can’t Live Without It.  2009: 136

Chapter 14:

101 Nakazawa, Donna Jackson.  The Autoimmune Epidemic.  2006: 255 (102) (103) (104)

105 Lee, Dr. John R.  What Your Doctor May Not Tell You About Menopause.  The Breakthrough Book on Natural Hormone Balance.2004: 62 (106) (107)

108 Lee, Dr. John R.  What Your Doctor May Not Tell You About Menopause.  The Breakthrough Book on Natural Hormone Balance.2004:63

109 Robin E. Dodson,corresponding author1 Marcia Nishioka,2 Laurel J. Standley,1,3 Laura J. Perovich,1 Julia Green Brody,1 and Ruthann A. Rudel1; Endocrine Disruptors and Asthma-Associated Chemicals in Consumer Products; Environ Health Perspect. 2012 July; 120(7): 935–943

110 Song M, Kim YJ, Park YK, Ryu JC.; Changes in thyroid peroxidase activity in response to various chemicals; J Environ Monit. 2012 Aug;14(8):2121-6. doi: 10.1039/c2em30106g. Epub 2012 Jun 15.

111 Yamasaki K, Ishii S, Kikuno T, Minobe Y.; Endocrine-mediated effects of two benzene related compounds, 1-chloro-4-(chloromethyl)benzene and 1,3-diethyl benzene, based on subacute oral toxicity studies using rats; Food Chem Toxicol. 2012 Aug;50(8):2635-42. doi: 10.1016/j.fct.2012.05.035. Epub 2012 May 27

112 Goldner WS, Sandler DP, Yu F, Hoppin JA, Kamel F, Levan TD.; Pesticide use and thyroid disease among women in the Agricultural Health Study; Am J Epidemiol. 2010 Feb 15;171(4):455-64. doi: 10.1093/aje/kwp404. Epub 2010 Jan 8.

113 Sobel ES, Gianini J, Butfiloski EJ, Croker BP, Schiffenbauer J, Roberts SM.; Acceleration of autoimmunity by organochlorine pesticides in (NZB x NZW)F1 mice; Environ Health Perspect. 2005 Mar;113(3):323-8

114 Emara AM, Abo El-Noor MM, Hassan NA, Wagih AA; Immunotoxicity and hematotoxicity induced by tetrachloroethylene in egyptian dry cleaning workers; Inhal Toxicol. 2010 Feb;22(2):117-24 (115) (116) (117)

118 Masahiro Kawahara,* and Midori Kato-Negishi; Link between Aluminum and the Pathogenesis of Alzheimer’s Disease: The Integration of the Aluminum and Amyloid Cascade Hypotheses; Int J Alzheimers Dis. 2011; 2011: 276393.

119 Ferreira PC, Piai Kde A, Takayanagui AM, Segura-Muñoz SI; Aluminum as a risk factor for Alzheimer’s disease; Rev Lat Am Enfermagem. 2008 Jan-Feb;16(1):151-7.

120 Tomljenovic L, Shaw CA; Do aluminum vaccine adjuvants contribute to the rising prevalence of autism?; J Inorg Biochem. 2011 Nov;105(11):1489-99.

121 Tomljenovic L, Shaw CA; Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations; Lupus. 2012 Feb;21(2):223-30.

122 Tomljenovic L, Shaw CA; Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations; Lupus. 2012 Feb;21(2):223-30.

123 Vahter ME; Interactions between arsenic-induced toxicity and nutrition in early life; J Nutr. 2007 Dec;137(12):2798-804.

124 Hojsak I, Braegger C, Bronsky J, Campoy C, Colomb V, Decsi T, Domellöf M, Fewtrell M, Mis NF, Mihatsch W, Molgaard C, van Goudoever J; Arsenic in rice: a cause for concern; J Pediatr Gastroenterol Nutr. 2015 Jan;60(1):142-5.

125 Ciarrocca M, Tomei F, Caciari T, Cetica C, Andrè JC, Fiaschetti M, Schifano MP, Scala B, Scimitto L, Tomei G, Sancini A; Exposure to arsenic in urban and rural areas and effects on thyroid hormones; Inhal Toxicol. 2012 Aug;24(9):589-98.

126 Jennifer C. Davey, Athena P. Nomikos, Manida Wungjiranirun, Jenna R. Sherman, Liam Ingram, Cavus Batki, Jean P. Lariviere, and Joshua W. Hamilton; Arsenic as an Endocrine Disruptor: Arsenic Disrupts Retinoic Acid Receptor–and Thyroid Hormone Receptor–Mediated Gene Regulation and Thyroid Hormone–Mediated Amphibian Tail Metamorphosis; Environ Health Perspect. 2008 Feb; 116(2): 165–172.

127 Järup L; Cadmium overload and toxicity; Nephrol Dial Transplant. 2002;17 Suppl 2:35-9.

128 Aimin Chen,corresponding author Stephani S. Kim, Ethan Chung, and Kim N. Dietrich; Thyroid Hormones in Relation to Lead, Mercury, and Cadmium Exposure in the National Health and Nutrition Examination Survey, 2007–2008; Environ Health Perspect. 2013 Feb; 121(2): 181–186.

129 Hammouda F, Messaoudi I, El Hani J, Baati T, Saïd K, Kerkeni A; Reversal of cadmium-induced thyroid dysfunction by selenium, zinc, or their combination in rat; Biol Trace Elem Res. 2008 Winter;126(1-3):194-203. doi: 10.1007/s12011-008-8194-8. Epub 2008 Aug 8.

130 Bigazzi PE; Autoimmunity and heavy metals; Lupus. 1994 Dec;3(6):449-53.

131 Liang QR, Liao RQ, Su SH, Huang SH, Pan RH, Huang JL; [Effects of lead on thyroid function of occupationally exposed workers]; Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2003 Apr;21(2):111-3.

132 Robins JM, Cullen MR, Connors BB, Kayne RD; Depressed thyroid indexes associated with occupational exposure to inorganic lead; Arch Intern Med. 1983 Feb;143(2):220-4.

133 Mishra KP; Lead exposure and its impact on immune system: a review; Toxicol In Vitro. 2009 Sep;23(6):969-72. (134)


Chapter 15:

136 Ercolini AM, Miller SD. The role of infections in autoimmune disease; Clin Exp Immunol. 2009 Jan;155(1):1-15

137 Kim B, Kaistha SD, Rouse BT.; Viruses and autoimmunity; Autoimmunity. 2006 Feb;39(1):71-7.

138 Delogu LG, Deidda S, Delitala G, Manetti R.; Infectious diseases and autoimmunity; J Infect Dev Ctries. 2011 Oct 13;5(10):679-87

139 Oldstone MB; Molecular mimicry and immune-mediated diseases; FASEB J. 1998 Oct;12(13):1255-65

140 Akahori H, Takeshita Y, Saito R, Kaneko S, Takamura T.; Graves’ disease associated with infectious mononucleosis due to primary Epstein-Barr virus infection: report of 3 cases; Intern Med. 2010;49(23):2599-603. Epub 2010 Dec 1

141 Nagata K, Fukata S, Kanai K, Satoh Y, Segawa T, Kuwamoto S, Sugihara H, Kato M, Murakami I, Hayashi K, Sairenji T.; The influence of Epstein-Barr virus reactivation in patients with Graves’ disease; Viral Immunol. 2011 Apr;24(2):143-9. doi: 10.1089/vim.2010.0072

142 Cecilia Söderberg-Nauclér; Autoimmunity induced by human cytomegalovirus in patients with systemic lupus erythematosus; Arthritis Res Ther. 2012; 14(1): 101.

143 Tozzoli R, Barzilai O, Ram M, Villalta D, Bizzaro N, Sherer Y, Shoenfeld Y.; Infections and autoimmune thyroid diseases: parallel detection of antibodies against pathogens with proteomic technology; Autoimmun Rev. 2008 Dec;8(2):112-5. doi: 10.1016/j.autrev.2008.07.013

144 Salisbury S, Embil JA.; Graves disease following congenital cytomegalovirus infection; J Pediatr. 1978 Jun;92(6):954-5

145 Hepatitis C PubMed Health

146 Trikudanathan GV, Ahmad I, Israel JL.; Concurrent autoimmune hepatitis and grave’s disease in hepatitis C during pegylated interferon α-2a and ribavirin therapy; Saudi J Gastroenterol. 2011 Sep-Oct;17(5):348-52

147 Brix TH, Hansen PS, Hegedüs L, Wenzel BE.; Too early to dismiss Yersinia enterocolitica infection in the aetiology of Graves’ disease: evidence from a twin case-control study; Clin Endocrinol (Oxf). 2008 Sep;69(3):491-6. doi: 10.1111/j.1365-2265.2008.03227.x. Epub 2008 Feb 18

148 Tomer Y, Davies TF.; Infection, thyroid disease, and autoimmunity; Endocr Rev. 1993 Feb;14(1):107-20

149 Corapçioğlu D, Tonyukuk V, Kiyan M, Yilmaz AE, Emral R, Kamel N, Erdoğan G.; Relationship between thyroid autoimmunity and Yersinia enterocolitica antibodies; Thyroid. 2002 Jul;12(7):613-7

150 Bassi V, Santinelli C, Iengo A, Romano C.; Identification of a correlation between Helicobacter pylori infection and Graves’ disease; Helicobacter. 2010 Dec;15(6):558-62. doi: 10.1111/j.1523-5378.2010.00802.

151 Bassi V, Marino G, Iengo A, Fattoruso O, Santinelli C.; Autoimmune thyroid diseases and Helicobacter pylori: the correlation is present only in Graves’s disease.; World J Gastroenterol. 2012 Mar 14;18(10):1093-7. doi: 10.3748/wjg.v18.i10.1093.

152 Benvenga S, Guarneri F, Vaccaro M, Santarpia L, Trimarchi F.; Homologies between proteins of Borrelia burgdorferi and thyroid autoantigens; Thyroid. 2004 Nov;14(11):964-6

153 Ettefagh KA, Burns JT, Junio HA, Kaatz GW, Cech NB.; Goldenseal (Hydrastis canadensis L.) extracts synergistically enhance the antibacterial activity of berberine via efflux pump inhibition; Planta Med. 2011 May;77(8):835-40. doi: 10.1055/s-0030-1250606. Epub 2010 Dec 14

154 Zhang LJ, Zhang LJ, Quan W, Wang BB, Shen BL, Zhang TT, Kang Y.; Berberine inhibits HEp-2 cell invasion induced by Chlamydophila pneumoniae infection; J Microbiol. 2011 Oct;49(5):834-40. doi: 10.1007/s12275-011-1051-z. Epub 2011 Nov 9

155 Sun D, Abraham SN, Beachey EH.; Influence of berberine sulfate on synthesis and expression of Pap fimbrial adhesin in uropathogenic Escherichia coli; Antimicrob Agents Chemother. 1988 Aug;32(8):1274-7

156 Pozzatti P, Scheid LA, Spader TB, Atayde ML, Santurio JM, Alves SH.; In vitro activity of essential oils extracted from plants used as spices against fluconazole-resistant and fluconazole-susceptible Candida spp; Can J Microbiol. 2008 Nov;54(11):950-6. doi: 10.1139/w08-097

157 Soylu S, Yigitbas H, Soylu EM, Kurt S.; Antifungal effects of essential oils from oregano and fennel on Sclerotinia sclerotiorum; J Appl Microbiol. 2007 Oct;103(4):1021-30

158 Force M, Sparks WS, Ronzio RA.; Inhibition of enteric parasites by emulsified oil of oregano in vivo; Phytother Res. 2000 May;14(3):213-4

159 Ankri S, Mirelman D; Antimicrobial properties of allicin from garlic; Microbes Infect. 1999 Feb;1(2):125-9

160 Aydin A, Ersöz G, Tekesin O, Akçiçek E, Tuncyürek M.; Garlic oil and Helicobacter pylori infection; Am J Gastroenterol. 2000 Feb;95(2):563-4

161 Ankri S, Mirelman D.; Antimicrobial properties of allicin from garlic; Microbes Infect. 1999 Feb;1(2):125-9

162 Ross ZM, O’Gara EA, Hill DJ, Sleightholme HV, Maslin DJ.; Antimicrobial properties of garlic oil against human enteric bacteria: evaluation of methodologies and comparisons with garlic oil sulfides and garlic powder; Appl Environ Microbiol. 2001 Jan;67(1):475-80

163 Dabos KJ, Sfika E, Vlatta LJ, Giannikopoulos G.; The effect of mastic gum on Helicobacter pylori: a randomized pilot study; Phytomedicine. 2010 Mar;17(3-4):296-9. doi: 10.1016/j.phymed.2009.09.010. Epub 2009 Oct 29

164 Farhad U. Huwez, M.R.C.P., Ph.D; Mastic Gum Kills Helicobacter pylori; N Engl J Med 1998; 339:1946December 24, 1998DOI: 10.1056/NEJM199812243392618

165 Reis SR, Valente LM, Sampaio AL, Siani AC, Gandini M, Azeredo EL, D’Avila LA, Mazzei JL, Henriques Md, Kubelka CF.; Immunomodulating and antiviral activities of Uncaria tomentosa on human monocytes infected with Dengue Virus-2; Int Immunopharmacol. 2008 Mar;8(3):468-76. doi: 10.1016/j.intimp.2007.11.010. Epub 2007 Dec 26

166 Herrera DR, Tay LY, Rezende EC, Kozlowski VA Jr, Santos EB.; In vitro antimicrobial activity of phytotherapic Uncaria tomentosa against endodontic pathogens; J Oral Sci. 2010 Sep;52(3):473-6

167 Na X, Kelly C.; Probiotics in clostridium difficile Infection; J Clin Gastroenterol. 2011 Nov;45 Suppl:S154-8. doi: 10.1097/MCG.0b013e31822ec787

168 Krasowska A, Murzyn A, Dyjankiewicz A, Łukaszewicz M, Dziadkowiec D.; The antagonistic effect of Saccharomyces boulardii on Candida albicans filamentation, adhesion and biofilm formation; FEMS Yeast Res. 2009 Dec;9(8):1312-21. doi: 10.1111/j.1567-1364.2009.00559.x. Epub 2009 Aug 5

169 Jawhara S, Poulain D.; Saccharomyces boulardii decreases inflammation and intestinal colonization by Candida albicans in a mouse model of chemically-induced colitis; Med Mycol. 2007 Dec;45(8):691-700 (170) (171)

172 Valipe SR, Nadeau JA, Annamali T, Venkitanarayanan K, Hoagland T; In vitro antimicrobial properties of caprylic acid, monocaprylin, and sodium caprylate against Dermatophilus congolensis; Am J Vet Res. 2011 Mar;72(3):331-5. doi: 10.2460/ajvr.72.3.331

173 Nair MK, Joy J, Vasudevan P, Hinckley L, Hoagland TA, Venkitanarayanan KS.; Antibacterial effect of caprylic acid and monocaprylin on major bacterial mastitis pathogens; J Dairy Sci. 2005 Oct;88(10):3488-95

174 Omura Y, O’Young B, Jones M, Pallos A, Duvvi H, Shimotsuura Y.; Caprylic acid in the effective treatment of intractable medical problems of frequent urination, incontinence, chronic upper respiratory infection, root canalled tooth infection, ALS, etc., caused by asbestos & mixed infections of Candida albicans, Helicobacter pylori & cytomegalovirus with or without other microorganisms & mercury; Acupunct Electrother Res. 2011;36(1-2):19-64

175 Eliezer Menezes Pereira,1 Thelma de Barros Machado,2 Ivana Correa Ramos Leal,3 Desyreé Murta Jesus,4 Clarissa Rosa de Almeida Damaso,4 Antonio Ventura Pinto,3 Marcia Giambiagi-deMarval,1 Ricardo Machado Kuster,3 and Kátia Regina Netto dos Santos; Tabebuia avellanedae naphthoquinones: activity against methicillin-resistant staphylococcal strains, cytotoxic activity and in vivo dermal irritability analysis; Ann Clin Microbiol Antimicrob. 2006; 5: 5

176 Morrill K, May K, Leek D, Langland N, Jeane LD, Ventura J, Skubisz C, Scherer S, Lopez E, Crocker E, Peters R, Oertle J, Nguyen K, Just S, Orian M, Humphrey M, Payne D, Jacobs B, Waters R, Langland J.; Spectrum of antimicrobial activity associated with ionic colloidal silver; J Altern Complement Med. 2013 Mar;19(3):224-31. doi: 10.1089/acm.2011.0681. Epub 2012 Sep 27

177 van Hasselt P, Gashe BA, Ahmad J.; Colloidal silver as an antimicrobial agent: fact or fiction?; J Wound Care. 2004 Apr;13(4):154-5

178 Yıldız K, Başalan M, Duru O, Gökpınar S.; Antiparasitic efficiency of Artemisia absinthium on Toxocara cati in naturally infected cats; Turkiye Parazitol Derg. 2011;35(1):10-4. doi: 10.5152/tpd.2011.03

179 Tariq KA, Chishti MZ, Ahmad F, Shawl AS.; Anthelmintic activity of extracts of Artemisia absinthium against ovine nematodes; Vet Parasitol. 2009 Mar 9;160(1-2):83-8. doi: 10.1016/j.vetpar.2008.10.084. Epub 2008 Oct 28

180 Minjung Lee, Myoungki Son, Eunhyun Ryu, Yu Su Shin, Jong Gwang Kim, Byung Woog Kang, Gi-Ho Sung, Hyosun Cho, and Hyojeung Kang; Quercetin-induced apoptosis prevents EBV infection; Oncotarget. 2015 May 20; 6(14): 12603–12624. (181) (182) (183)

Chapter 16:                

184 Nakazawa, Donna Jackson.  The Autoimmune Epidemic.  2006: 72 (185) (186) (187)

Chapter 17:

188 Moore, Elaine A. and Moore, Lisa.  Graves’ Disease, A Practical Guide.  2001: 107

189 Moore, Elaine A. and Moore, Lisa.  Graves’ Disease, A Practical Guide.  2001: 109

190 Balaji B. Ganesh,1,,2 Palash Bhattacharya,1 Anupama Gopisetty,1 and Bellur S. Prabhakarcorresponding author; Role of Cytokines in the Pathogenesis and Suppression of Thyroid Autoimmunity; J Interferon Cytokine Res. 2011 October; 31(10): 721–731.

191 Drugarin D, Negru S, Koreck A, Zosin I, Cristea C.; The pattern of a T(H)1 cytokine in autoimmune thyroiditis; Immunol Lett. 2000 Feb 1;71(2):73-7

192 Kocjan T, Wraber B, Repnik U, Hojker S.; Changes in Th1/Th2 cytokine balance in Graves’ disease; Pflugers Arch. 2000;440(5 Suppl):R94-5

193 What is the role of radioiodine uptake measurement and thyroid scintigraphy in the diagnosis and

management of hyperthyroidism? By: Franklyn, Jayne A.. Clinical Endocrinology, Jan2010, Vol. 72 Issue 1, p11-12, 2p


Chapter 18:

195 Increased long-term cardiovascular morbidity among patients treated with radioactive iodine for hyperthyroidism. By: Metso, Saara; Auvinen, Anssi; Salmi, Jorma; Huhtala, Heini; Jaatinen, Pia. Clinical Endocrinology, Mar2008, Vol. 68 Issue 3, p450-457, 8p, 3 Charts, 2 Graphs

196 TMortality after the Treatment of Hyperthyroidism with Radioactive Iodine. By: Franklyn, J.A.; Maisonneuve, P.; Sheppard, M.C.; Betteridge, J.; Boyle, P.. New England Journal of Medicine; 03/12/98, Vol. 338 Issue 11, p712-718, 1p (197) (198) (199) (200)

201 Choice of Therapy in Young Adults with Hyperthyroidism of Graves’ Disease.. By: Dunn, John T.. Annals of Internal Medicine, Jun84, Vol. 100 Issue 6, p891, 3p

Chapter 19:

202 He CT, Hsieh AT, Pei D, Hung YJ, Wu LY, Yang TC, Lian WC, Huang WS, Kuo SW.; Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves’ hyperthyroidism; Clin Endocrinol (Oxf). 2004 Jun;60(6):676-81. (203) (204) (205) (206) (207)

Chapter 20:

208 Frost L, Vestergaard P, Mosekilde L.; Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study; Arch Intern Med. 2004 Aug 9-23;164(15):1675-8

209 Jayaprasad N, MBBS, MD and Johnson Francis, MBBS, MD, DM; Atrial Fibrillation and Hyperthyroidism; Indian Pacing Electrophysiol Jv.5(4); Oct-Dec 2005PMC1431605 (210) (211) (212)

213 Tadzer I, Simova N, Karanfilski B, Korubin V, Serafimov N, Miceva S, Loparska S, Vaskova O.; Extended long-term drug monotherapy of Graves’ disease; Acta Med Iugosl. 1989;43(3):181-7

Chapter 21: (214) (215) (216) (217) (218) (219) (220) (221) (222) (223) (224) (225)


227 Geanina Popoveniuc, MDa,b and Jacqueline Jonklaas, MD, PhDa,; Thyroid Nodules; Med Clin North Am. 2012 March; 96(2): 329–349.

228 Castro MR, Gharib H.; Thyroid fine-needle aspiration biopsy: progress, practice, and pitfalls; Endocr Pract. 2003 Mar-Apr;9(2):128-36

229 Gharib H, Goellner JR.; Fine-needle aspiration biopsy of the thyroid: an appraisal; Ann Intern Med. 1993 Feb 15;118(4):282-9

230 Syed Z. Ali; Stephanie A. Fish; Richard B. Lanman; Gregory W. Randolph; Julie Ann Sosa; Use of the Afirma® Gene Expression Classifier for Preoperative Identification of Benign Thyroid Nodules with Indeterminate Fine Needle Aspiration Cytopathology; FEBRUARY 11, 2013 · DIAGNOSTIC (231)

232 Continuing Controversies in the Management of Thyroid Nodules. By: Castro, M. Regina; Gharib, Hossein. Annals of Internal Medicine, 6/7/2005, Vol. 142 Issue 11, p926-W-217, 7p (233)

234 Porterfield JR Jr, Thompson GB, Farley DR, Grant CS, Richards ML.; Evidence-based management of toxic multinodular goiter (Plummer’s Disease); World J Surg. 2008 Jul;32(7):1278-84.

235 Ríos A, Rodríguez JM, Balsalobre MD, Torregrosa NM, Tebar FJ, Parrilla P.; Results of surgery for toxic multinodular goiter; Surg Today. 2005;35(11):901-6 (236) (237)

238 Guy E. Abraham, M.D.1 and David Brownstein, M.D; Validation of the orthoiodosupplementation program: A Rebuttal of Dr. Gaby’s Editorial on iodine

239 Mishra A, Mishra SK.; Thyroid nodules in Graves’ disease: implications in an endemically iodine deficient area; J Postgrad Med. 2001 Oct-Dec;47(4):244-7

Chapter 22:

240 Wiersinga WM, Bartalena L.; Epidemiology and prevention of Graves’ ophthalmopathy; Thyroid. 2002 Oct;12(10):855-60

241 Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review. By: Acharya, Shamasunder H.; Avenell, Alison; Philip, Sam; Burr, Jennifer; Bevan, John S.; Abraham, Prakash. Clinical Endocrinology, Dec2008, Vol. 69 Issue 6, p943-950, 8p, 4 Diagrams, 2 Charts

242 Wiersinga WM.; Management of Graves’ ophthalmopathy; Nat Clin Pract Endocrinol Metab. 2007 May;3(5):396-404 (243) (244) (245) (246) (247) (248) (249) (250) (251) (252) (253) (254) (255) (256) (257)

258 Wiersinga WM.; Management of Graves’ ophthalmopathy; Nat Clin Pract Endocrinol Metab. 2007 May;3(5):396-404

259 Stiebel-Kalish H, Robenshtok E, Gaton DD.; Pathophysiology of Graves’ ophthalmopathy; Pediatr Endocrinol Rev. 2010 Mar;7 Suppl 2:178-81

Chapter 23:

260 Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K, Kosuga Y, Suzuki M, Matsumoto M, Kunii Y, Watanabe N, Mukasa K, Ito K, Ito K; Treatment of graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation; J Clin Endocrinol Metab. 2012 Jul;97(7):2396-403. doi: 10.1210/jc.2011-2860. Epub 2012 Apr 30

261 Chattaway JM, Klepser TB.; Propylthiouracil versus methimazole in treatment of Graves’ disease during pregnancy; Ann Pharmacother. 2007 Jun;41(6):1018-22. Epub 2007 May 15

262 Hathcock JN, Hattan DG, Jenkins MY, McDonald JT, Sundaresan PR, Wilkening VL.; Evaluation of vitamin A toxicity; Am J Clin Nutr. 1990 Aug;52(2):183-202

263 Räikkönen K, Pesonen AK, Heinonen K, Lahti J, Komsi N, Eriksson JG, Seckl JR, Järvenpää AL, Strandberg TE.; Maternal licorice consumption and detrimental cognitive and psychiatric outcomes in children; Am J Epidemiol. 2009 Nov 1;170(9):1137-46

264 Francis S. Balucan,* Syed A. Morshed, and Terry F. Davies; Thyroid Autoantibodies in Pregnancy: Their Role, Regulation and Clinical Relevance; J Thyroid Res. 2013; 2013: 182472.

265 Casey BM, Dashe JS, Wells CE, McIntire DD, Leveno KJ, Cunningham FG.; Subclinical hyperthyroidism and pregnancy outcomes; Obstet Gynecol. 2006 Feb;107(2 Pt 1):337-41

Chapter 24:

266 Nayak B, Burman K.; Thyrotoxicosis and thyroid storm; Endocrinol Metab Clin North Am. 2006 Dec;35(4):663-86, vii (267) (268)

Chapter 25: (269) (270) (271) (272)

273 Pinchera A, Aghini-Lombardi F, Antonangeli L, Vitti P.; Multinodular goiter. Epidemiology and prevention; Ann Ital Chir. 1996 May-Jun;67(3):317-25

274 Moalem J, Suh I, Duh QY.; Treatment and prevention of recurrence of multinodular goiter: an evidence-based review of the literature; World J Surg. 2008 Jul;32(7):1301-12.

275 T S Reeve, L Delbridge, A Cohen, and P Crummer; Total thyroidectomy. The preferred option for multinodular goiter; Ann Surg. 1987 December; 206(6): 782–786.

276 Snook KL, Stalberg PL, Sidhu SB, Sywak MS, Edhouse P, Delbridge L.; Recurrence after total thyroidectomy for benign multinodular goiter; World J Surg. 2007 Mar;31(3):593-8; discussion 599-600

277 Daali M, Tajedine T.; Toxic multinodular goiter; Ann Endocrinol (Paris). 2003 Oct;64(4):284-8

278 Cerci C, Cerci SS, Eroglu E, Dede M, Kapucuoglu N, Yildiz M, Bulbul M.; Thyroid cancer in toxic and non-toxic multinodular goiter; J Postgrad Med. 2007 Jul-Sep;53(3):157-60

279 Brito JP, Yarur AJ, Prokop LJ, McIver B, Murad MH, Montori VM; Prevalence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta-analysis; Thyroid. 2013 Apr;23(4):449-55. doi: 10.1089/thy.2012.0156

Chapter 28:

280. Brown N, Panksepp J.; Low-dose naltrexone for disease prevention and quality of life; Med Hypotheses. 2009 Mar;72(3):333-7

281. Rahn KA, McLaughlin PJ, Zagon IS.; Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis; Brain Res. 2011 Mar 24;1381:243-53.

282. Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G.; A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis; Mult Scler. 2008 Sep;14(8):1076-83

  1. 283. Agrawal YP.; Low dose naltrexone therapy in multiple sclerosis; Med Hypotheses. 2005;64(4):721-4. (284)

  1. 285. Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F.; Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine; Eur J Endocrinol. 2005 May;152(5):695-701.
  2. 286. Azizi F, Yousefi V, Bahrainian A, Sheikholeslami F, Tohidi M, Mehrabi Y.; Long-term continuous methimazole or radioiodine treatment for hyperthyroidism; Arch Iran Med. 2012 Aug;15(8):477-84 (287) (288) (289) (290) (291) (292)

Chapter 29: (293)

  1. 294. Gerster H.; Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)?; Int J Vitam Nutr Res. 1998;68(3):159-73.